GSK vs Regeneron Pharmaceuticals

GSK (GSK), health care, and Regeneron Pharmaceuticals (REGN), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

GSK and Regeneron Pharmaceuticals are valued at about the same: $99.1B and $99.2B. GSK trades at 17.2 times earnings and Regeneron Pharmaceuticals at 21.2; operating margins in their latest fiscal years were 24.3% and 24.9%. Over the past year GSK's share price has moved +6.42% and Regeneron Pharmaceuticals's +31.3%.

Key facts

GSK market value
$99.1B
Regeneron Pharmaceuticals market value
$99.2B
GSK P/E
17.2
Regeneron Pharmaceuticals P/E
21.2
GSK revenue
$43.4BFY to 2025-12-31
Regeneron Pharmaceuticals revenue
$14.3BFY to 2025-12-31
Superinvestors holding both
2

Market values as of .

GSK vs Regeneron Pharmaceuticals: every measure side by side
Measure GSK Regeneron Pharmaceuticals
SectorHealth CareHealth Care
Country United Kingdom United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$99.1Blower$99.2Bhigher
Revenue$43.4Bhigher$14.3Blower
Earnings$7.6Bhigher$4.5Blower
Employees66,841higher15,410lower
Total assets$81.1Bhigher$40.6Blower
Valuation
P/E17.2lower21.2higher
P/S2.3lower6.9higher
P/B—2.9
Dividend yield—0.39%
Profitability
Operating margin24.3%lower24.9%higher
Balance sheet
Net assets$21.7Blower$31.3Bhigher
Total liabilities$59.9Bhigher$9.3Blower
Total debt$19.2Bhigher$2Blower
Cash on hand$4.5Bhigher$3.1Blower
Price change
Today-1.90%lower+0.66%higher
1 year+6.42%lower+31.3%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": GSK / Regeneron Pharmaceuticals). Who owns GSK · Who owns REGN

Further comparisons

Learn

Questions and answers

Which is bigger, GSK or Regeneron Pharmaceuticals?

By market value, Regeneron Pharmaceuticals is the larger: $99.2B against $99.1B for GSK. By revenue in its latest fiscal year, GSK is the larger: $43.4B against $14.3B for Regeneron Pharmaceuticals.

Which has the higher P/E ratio?

Regeneron Pharmaceuticals: 21.2, against 17.2 for GSK. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Regeneron Pharmaceuticals: 24.9%, against 24.3% for GSK. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has more debt?

GSK: $19.2B, against $2B for Regeneron Pharmaceuticals. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both GSK and Regeneron Pharmaceuticals?

In their latest 13F filings, Dodge & Cox team and Jeremy Grantham (co-founder) hold both.

Cite this page

Funkfolio, “GSK vs Regeneron Pharmaceuticals”, data as of 17 November 2026. https://funkfolio.com/compare/gsk-vs-regn

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.